Global Competition Review Recognizes Arnold & Porter in 2026 ‘Foreign Investment Control’ Guide

Global Competition Review recognized Arnold & Porter in the inaugural edition of its “GCR 100: Foreign Investment Control” guide. Based on independent research into firms’ scale, geographic and sectoral reach, and the work they handle, GCR shines “a spotlight on the most important firms and public affairs consultancies that advise clients on foreign investment issues.”

Arnold & Porter’s “foreign investment practice is shaped by its deep engagement in regulated industries and by the breadth of its Brussels and London teams” and “its center of gravity lies in sectors where investment screening has become increasingly intricate – particularly life sciences, pharmaceuticals, medical devices, technology and cybersecurity,” according to the publication. “A notable feature of the practice is the strategic orientation of its advice” as the group “is not limited to legal risk assessment but works closely with clients to navigate practical issues that arise from fragmented screening frameworks across the UK and EU.” GCR highlighted the firm’s work advising Novo Nordisk on its $16.5 billion acquisition of Catalent, Pfizer on its $43 billion acquisition of Seagen, and Palo Alto Networks on its acquisition of IBM’s QRadar SaaS business, among other significant matters.